Aberrations in epidermal growth factor receptor (EGFR/ErbB1) are the most common oncogenic alterations in glioblastoma multiforme (GBM), the most common primary brain tumor. Interactions between wild-type (wt) and mutant EGFRs and their subsequent activation are of biologic and potential therapeutic importance in GBMs. We recently showed that in situ proximity ligation assay (PLA) allows for quantitative evaluation of EGFR dimerization and activation in intact cells. Using this in situ platform, we show the aberrant homo-/heterodimeric properties of EGFRvIII and EGFRc958 mutants, the two most common EGFR mutants in GBMs. In addition, dimer phosphoactivation status could be detected by PLA with superior signal-noise ratio (>17-fold) and sensitivity (>16-fold) than immunofluorescence-based phospho-EGFR measurements. Dimer activation analysis indicated quantitative activation differences of mutant dimers. These aberrant features were not overexpression dependent but appeared independent of cellular expression levels, suggesting inherent properties of the mutant receptors. Moreover, we observed in situ detection of EGFRwt-EGFRvIII heterodimerization in GBM specimens, supporting our cell line observations. Notably, currently used anti-EGFR therapeutics, such as cetuximab, matuzumab, and panitumumab, could effectively block EGFRwt dimerization and activation but did not equally impair EGFRvIII homodimers, EGFRwt-EGFRvIII, or EGFRvIII-EGFRc958 heterodimers. EGFRvIII appears to have intrinsic phosphoactivation independent of dimerization as matuzumab blockade of homodimerization had no effect on receptor phosphorylation levels. These data suggest differences in the dimerization-blocking efficacy of EGFR monoclonal antibodies as mutant EGFR dimer configurations prevalent in GBMs can evade blockade by anti-EGFR treatments. Further studies are warranted to evaluate whether this evasion contributes to poor therapeutic response or resistance. Mol Cancer Res; 10(3); 428-40. Ó2012 AACR.
Introduction
The epidermal growth factor receptor (EGFR) is deregulated in several human malignancies. In glioblastoma multiforme (GBM), the most common and malignant adult central nervous system tumor, EGFR is frequently observed to undergo genomic amplification and is usually overexpressed at the protein level (1, 2) . In addition, several mutant forms of the receptor are often detected in cases where the wild-type receptor (EGFRwt) has undergone genomic amplification. Notably, the most frequent mutation is the oncogenic EGFRvIII (delta2-7) seen in about 40% of cases where the EGFRwt is amplified (3) . EGFRvIII expression has also been reported in several other human cancers including non-small cell lung, breast, prostate, ovarian, and head and neck cancers, albeit at lower frequency and not at the level of genomic rearrangements (4, 5) . The second most common EGFR mutation is the EGFRc958 variant, observed in about 20% of cases where the EGFRwt is amplified and is expressed mostly, if not always, in tumors that also express the EGFRvIII alteration (6, 7) .
Recent reports have suggested that EGFR dimerization has an important role in sustaining a tumorigenic state in GBMs and evading EGFR-targeted therapies (8) . Inhibitors that selectively impair dimerization of EGFRs are hence of potential interest requiring understanding of the intricacies of EGFR dimerization, specifically the interaction capacity of EGFR mutants that are relevant in the context of GBMs. The possibility of dimerization among EGFRwt and EGFR mutants may be an important signal generator in GBMs and may confer a mechanism for differential strength and type of signaling, altered downregulation and trafficking, as well as facilitating resistance to EGFR-targeted therapies. While previous studies have investigated the ability of GBM-relevant EGFR mutants to dimerize using traditional biochemical methodologies, such as chemical cross-linking and immunoprecipitations, the interaction status still remains controversial (9) . Figure 1 . A, dual binding of primary antibodies to epitope-tagged EGFR followed by species-selective PLA probe binding provides a scaffold to allow hybridization of connector oligos (left). Ligation of connector oligos and polymerase-mediated amplification creates a concatemeric amplification product that can then be visualized by hybridization of complementary fluorescence-labeled probes to the amplification product (right). B, immunoblot analysis of EGFR expression in transfected CHOK1 cells with antibodies to EGFR, FLAG, MYC, and b-actin. CHOK1, nontransfected CHOK1 cells. C, analysis of surface EGFR expression levels in cells stained with fluorescently labeled anti-EGFR antibody. Solid horizontal line indicates maximum fluorescence levels (autofluorescence) of CHOK1-stained parental cells. Histogram signifies fluorescence due to antibody binding. Representative histograms of duplicate experiments are shown. D, detection of pEGFR1068 on CHOK1-EGFR-MYC serum-starved (top) and EGF-stimulated (bottom) cells by immunofluorescence (IF) microscopy (left) or in situ PLA (right). Inset, total EGFR stain (green) was included in analysis to identify EGFR-positive transfected cells. Images of the condition with the highest SNRs are presented. E, quantitative comparison of SNR and sensitivity of pEGFR1068 detection by immunofluorescence and PLA.
Recently, we have described our work developing and optimizing a novel in situ proximity ligation assay (PLA) for quantitative EGFR dimerization analysis on intact cells (10) . Briefly, antibody-based proximity probes conjugated to oligonucleotide extensions bind to monomers of epitopetagged EGFR and are brought into requisite hybridization proximity upon receptor dimerization. These proximity probes guide the formation of circular DNA strands that are subsequently amplified to create detection sites for fluorescent probes and act as a reporter for protein dimerization (Fig. 1A) . Each fluorescently labeled bundle represents the formation of one molecular interaction, facilitating the visualization, quantitation, and localization of in situ EGFR dimer formation in individual cells. In the present body of work, we systematically analyzed the in situ homodimerization, heterodimerization, and phosphoactivation states of EGFRwt, EGFRvIII, and EGFRc958 using PLA. In addition, studies were conducted to assess the ability of clinically approved and investigational antibody-based EGFR therapies to block mutant receptor dimerization, activation, and downstream signaling. We also provide, to our knowledge, the first in situ evidence of EGFRwt-EGFRvIII heterodimerization in GBM specimens and a potential novel diagnostic or theranostic marker.
Materials and Methods

Cell culture and transfections
Chinese hamster ovary (CHOK1) cells (American Type Culture Collection) were cultured in 1Â F-12K nutrient medium containing 10% fetal calf serum (Wisent). For imaging and PLA experiments, cells were grown to 70% confluency on 18 Â 18 mm 2 glass coverslips (Fisher Scientific) placed in 6-well plates (BD Biosciences) and transfected with indicated expression constructs using FuGENE HD (Roche) according to the manufacturer's instructions. After 6 hours, the transfection medium was changed to serum-free medium, incubated for another 18 hours, and subsequently fixed in 4% paraformaldehyde. For tetracycline (TET)-inducible expression experiments, CHOK1 TET-On (Clontech) cells were cultured in 90% high-glucose Dulbecco's Modified Eagle's Media (Wisent) containing 10% Tet System-Approved FBS. At 70% confluence, cells were transfected with tetracycline response element (TRE) expression constructs in the presence of doxycycline (Sigma) for 6 hours, serum-starved in the presence of doxycycline, and incubated for another 18 hours before beginning the experiment.
SDS-PAGE/immunoblotting
Cells were lysed in modified PLC lysis buffer and analyzed by SDS-PAGE as described previously (10) . Membranes were probed overnight at 4 C with antibodies to pEGFR1068, pAKT, AKT, pERK1/2, ERK, and p27 (1:1,000; Cell Signaling); EGFR (1:1,000; Upstate); FLAG and MYC (1:2,000; Sigma-Aldrich); and anti-b-actin antibodies (1:10,000; Sigma-Aldrich).
In situ PLA analyses in cultured cells
Cells were grown on coverslips and cotransfected with expression constructs as described in the Cell culture and transfection section. Transfected cells were stimulated with 100 ng/mL EGF for 3 minutes, washed, fixed and permeabilized, and blocked as described previously (10) . For EGFR dimerization analysis, mouse anti-MYC (1:1,000; SigmaAldrich) and rabbit anti-FLAG (1:200; Sigma-Aldrich) primary antibodies were used. EGFR phosphoactivation analysis was conducted using mouse anti-EGFR (1:400; Upstate) and rabbit anti-pEGFR1068 (1:400; Cell Signalling). In situ PLA was conducted following primary antibody incubation as described previously (10, 11) . PLA probe dilution/incubation time and rolling circle amplification (RCA) times were all optimized for this specific application. Fluorescein isothiocyanate (FITC) anti-actin (1:100; Abcam) or FITC anti-EGFR (1:50; Upstate), as indicated, were added during the PLA reaction. Coverslip samples were mounted and examined with a Zeiss Axiovert 200 M epifluorescence microscope under a 40Â objective.
Quantitative PLA image analysis
Images were collected using AxioVision acquisition software from several fields of view per condition per experiment. Typically, about 30 cells per condition were quantified using Blobfinder 3.1 (Centre for Image Analysis, Uppsala University, Uppsala, Sweden) semiautomated image analysis. Transfected cells were identified with an FITC anti-EGFR stain. Blobfinder analysis involved identifying cells using the signal from one focal plane of Hoechst nuclear stain (i.e., one nucleus per cell) and delineation of cellular boundaries. Point-like PLA signals were analyzed to define true signal as local intensity maximum above a background threshold. Blobfinder assignment of cellular boundary and separation of multinucleated structures was manually validated and adjusted for each cell included in the quantitation to ensure accurate approximation of cellular area. The number of PLA signals per cell was counted from 3 Z-plane images. Statistical analysis was conducted using GraphPad Prism 4.0 software. Two-tailed Student t tests were used for calculating the significance of the differences and significance was accepted when P < 0.05. Mean values AE SEM are presented from quantitation of at least 3 independent experiments.
pEGFR PLA SNR and sensitivity analysis Immunofluorescence was conducted as described previously (10) with rabbit anti-pEGFR1068 (Cell Signalling Technologies) at dilutions indicated in text and FITC anti-EGFR (1:50; Upstate). Samples were incubated with Texas Red anti-rabbit (Abcam) secondary antibodies, counterstained, and imaged as above. Single antibody in situ PLA was conducted as described in the In situ PLA analyses in cultured cells section using anti-rabbit PLA MINUS and anti-rabbit PLA PLUS secondary probes. The mean signal intensity of 10 pixels representative of "biologic" positive signal and 10 pixels representative of "biologic" negative signal was determined per condition for both the immunofluorescent and PLA images, using Adobe Photoshop (Adobe Systems Inc.). Signal-noise ratio (SNR) was calculated as follows: signal intensity "biologic" positive signal/signal intensity "biologic" negative signal.
Mean values of the SNR for 10 pixel pairs AE SEM are presented. PLA sensitivity was calculated as follows: PLA highest antibody dilution where SNR > 1/immunofluorescence (IF) highest antibody dilution where SNR > 1.
Targeting of EGFR dimerization with monoclonal antibodies
Anti-EGFR monoclonal antibodies (mAb) cetuximab (Erbitux; ImClone Systems Inc.) and panitumumab (Vectibix; Amgen) were purchased whereas matuzumab was gifted (EMD 72000; Merck KGaA).
Quantitative flow cytometry
The number of EGFRs per cell was determined by staining samples with Alexa Fluor-labeled anti-EGFR (1 mg/mL; Upstate) mAbs and conducting quantitative flow cytometry using Quantum Simply Cellular microbead standards (Bangs Laboratories Inc.) as described previously (12) . Fluorescence-activated cell-sorting (FACS) plots of microbead standards and receptor per cell versus fluorescent intensity calibration curves can be found in Supplementary  Fig. S1 .
In situ PLA analyses of formalin-fixed, paraffin-embedded GBM specimens A panel of GBM operative samples, verified by our neuropathology collaborator [Dr. S. Croul, University Health Network (UHN), University of Toronto, Toronto, Ontario, Canada], was characterized for EGFRwt/vIII status by reverse transcriptase-PCR ( Supplementary Fig. S3 ). Corresponding formalin-fixed, paraffin-embedded tissue sections were used, in accordance with UHN REB approval. Sections were deparaffinized, rehydrated, and washed in distilled H 2 O. Antigen retrieval was conducted by pepsin digestion [Digest All-3 (Invitrogen)]. All subsequent steps were conducted as described in the In situ PLA analyses in cultured cells section with the exception of secondary probe co-incubation for 90 minutes. Direct EGFRwt-EGFRvIII heterodimerization analysis was conducted using rabbit anti-EGFRvIII (1:200; Abcam) and mouse anti-EGFRwt (1:200; Dako).
Results and Discussion
EGFR epitope-tag expression levels in CHOK1 cells are similar to GBM specimens EGFR dimerization and activation features in GBMs, and other human cancers, are of considerable biologic and potential therapeutic importance. While much interest and focus has already been devoted to this issue, such studies have yielded conflicting results and also used experimental models with significant limitations (9, (12) (13) (14) (15) . Namely, the use of co-immunoprecipitations and chemical cross-linking followed by Western blot analysis is restricted in several ways. This analysis may not preserve transient or weak interactions, requires large amounts of cultured cells that may be difficult to obtain in certain cases, and the act of cell lysis does not preserve the subcellular environment in which certain interactions occur.
In the present body of work, we sought to revisit the issue of mutant EGFR dimerization and activation using a previously described in situ dimerization assay combining epitope tagging with PLA (10). Constitutive mammalian expression vectors were generated to impart mutually exclusive antibody-binding epitopes, whereby EGFRwt, EGFRvIII, and EGFRc958 proteins were tagged at the carboxyterminus with either a FLAG or MYC epitope-tag. Transient transfection into a CHOK1 cell line, devoid of endogenous EGFR expression, and immunoblot analysis revealed the appropriate molecular weight proteins expressed to qualitatively similar levels (Fig. 1B) . As shown previously (10), this epitope-tagging approach did not perturb the cellular localization or ligand-induced tyrosine phosphorylation of the receptors. To directly quantify the EGFR expression levels on the surface of these cells, quantitative flow cytometrybased measurements were used. As shown in Fig. 1C Fig. S1 ). Previous estimations of mutant EGFR expression levels in freshly disaggregated GBM biopsy tissue have suggested that the majority of samples express mutant receptors at about 10 5 receptors per cell (16) . The values in our experiments are therefore consistent with "disease-relevant" expression found in human GBMs.
PLA has higher SNR and sensitivity compared with standard techniques
To investigate the advantages of using PLA detection of pEGFR over traditional immunofluorescence detection, we conducted a "head-to-head" comparison of immunofluorescence pEGFR1068 detection against PLA-mediated detection of the same pEGFR1068 antibody. In this case, a "single recognition" (i.e., one primary antibody) PLA is used and a pair of MINUS and PLUS secondary probes raised in the same species are used. This approach was chosen to make the comparison conditions more equivalent, as the immunofluorescence approach is typically conducted using a single primary antibody as well. Immunofluorescent analysis of pEGFR was difficult to interpret, as the pEGFR signals of the EGFR-stimulated cells were very similar in appearance to the nonstimulated cells ( Fig. 1D, left; compare arrows, and nonspecific background signal indicated by Ã ). Using pEGFR PLA detection, the nonphosphorylated and phosphorylated forms of EGFR were clearly detected (Fig. 1D, right) . A striking difference between the immunofluorescent and PLA images was the reduced PLA "noise" signal in the nonphosphorylated samples. This can be attributed to absence of spurious secondary antibody binding; binding specificity of the Texas Red-labeled PLA detection oligos; or the amplification step which greatly enhances the local intensity of true signal. Quantitative image analysis of the PLA and immunofluorescence experiments confirmed that the PLA approach exhibited superior SNR (>17-fold) than immunofluorescence at low antibody dilutions and had more than 6-fold SNR even at very high antibody dilutions of 1:800 (Fig. 1E) . Consistent with this SNR advantage, pEGFR PLA was more sensitive (>16-fold) at detecting pEGFR even at antibody dilutions of 1:800. In principle, the PLA platform enables users the ability to monitor dimerization characteristics of various receptor tyrosine kinase, and more importantly, allows concurrent analysis of the respective activation state of those receptors.
Mutant EGFRs display aberrant dimerization characteristics
EGFR genomic amplification is observed in tumors that express mutant EGFRs such as EGFRvIII or EGFRc958. In addition, the EGFRc958 alteration is expressed mostly, if not always, in tumors that also express the EGFRvIII alteration (7). Thus, tumor coexpression suggests at least the potential for dimerization events to occur between EGFRwt and mutant EGFRs. To evaluate the dimerization features of EGFRwt and mutant EGFRs, we conducted quantitative in situ PLA on cells expressing various combinations of receptors. Homodimer formation was tested in cells coexpressing EGFRwt-MYC þ EGFRwt-FLAG, EGFRvIII-MYC þ EGFRvIII-FLAG, and EGFRc958-MYC þ EGFRc958-FLAG. In addition, heterodimer formation was tested in cells coexpressing EGFR constructs EGFRwt-MYC þ EGFRvIII-FLAG, EGFRwt-MYC þ EGFRc958-FLAG, and EGFRvIII-MYC þ EGFRc958-FLAG. Previously, we showed that PLA could detect and quantify EGFR dimerization on intact cells at single-cell resolution (10) . Consistent with previous data, preformed EGFRwt homodimers were detected even in without EGF conditions, although high levels of EGFRwt dimerization require the presence of EGF (refs. 17-20; Fig. 2A and B) . However, EGFRvIII homodimers were detected constitutively and showed no difference under without EGF or with EGF conditions ( Fig. 2A and B) . Fig. 2A and B) and were noticeably fewer in comparison to ligand-induced EGFRwt homodimers. Heterodimer quantification revealed reduced but persistent presence of EGFRwtEGFRvIII heterodimers compared with EGFRwt homodimers. While EGF stimulation showed a modest increase in EGFRwt-EGFRvIII dimer levels, this gain was not significant (P ¼ 0.2868). However, the elevated levels of EGFRwt-EGFRvIII dimers in the unstimulated condition (relative to EGFRwt dimers in the unstimulated condition) indicate that EGFRvIII has a dominant ligandindependent activity driving formation of this dimeric unit. The mutant EGFRvIII-EGFRc958 heterodimer had constitutive dimerization, with a slight but not significant (P ¼ 0.1453) increase in dimer levels following EGF stimulation. Another novel finding was that EGFRc958 showed a compromised ability to form both homodimers and EGFRwt-EGFRc958 heterodimers. This was not expected as EGFRc958 retains all the extracellular dimerization interfaces found in EGFRwt and also responds in a ligand-induced receptor-mediated dimerization mechanism. This impaired dimerization ability is likely due to the absence of recently described dimerization-related sequences which are absent in the EGFRc958-truncated receptor (21) . This detection by PLA of the extracellularly deleted EGFRvIII to dimerize with EGFRwt or EGFRc958 has been of debate and not been resolved with standard techniques to date.
Phosphoactivation status is quantitatively altered in mutant EGFR dimers
In addition to interaction detection, dual-recognition PLA can allow monitoring of posttranslational modifications on individual molecules. To directly measure the phosphoactivation status of EGFRs in CHOK1 cells, we sought to use the PLA approach using antibodies that would enable detection of the phosphorylation status on individual receptors. We hypothesized that the combination of antibodies targeted toward (i) the intracellular C-terminal region of EGFR and (ii) a unique epitope present only when tyrosine autophosphorylation occurs would enable detection of pEGFRs when subjected to subsequent dual-recognition PLA. To directly measure the phosphoactivation states of the EGFR homodimer and heterodimer configurations, the PLA dual-recognition approach was modified using mouse anti-EGFR (C-terminus) and rabbit anti-pEGFR1068 primary antibodies. The pEGFR1068 antibody selectively recognizes the phosphorylated form of Y-1068. Tyrosine 1068 is one of the major autophosphorylation sites critical for tumorigenicity, suggested to be an important site of interreceptor phospho-feedback connectivity, and is an accepted indicator of pEGFR status (14, 22) . To test the possibility of measuring pEGFRs using in situ PLA, CHOK1 cells were transfected with EGFRwt-FLAG and subjected to in situ pEGFR PLA using anti-EGFR and anti-pEGFR1068 primary antibodies. Of note, the Y-1068 site is deleted in EGFRc958 and hence not detected by the pY-1068 antibody used in our experiments. This fact served as an important technical and biologic negative control, as shown by EGFRc958 homodimers not generating any observable PLA signal irrespective of EGF stimulation (Fig. 3B) . In contrast, EGF stimulation of EGFRwt-transfected CHOK1 cells showed an increase in PLA signal (Fig. 3A , bottom left) compared with those cells that were transfected but not stimulated with EGF (Fig. 3A, top left) . Autophosphorylation of Y-1068 is dependent on the competence of the receptor's kinase domain as cells treated with the tyrosine kinase inhibitor AG1478 (Fig. 3A , bottom right) failed to generate an increase in PLA signal. Taken together, these data show that the observed signal was dependent on EGFR activation and, moreover, the EGFR/pEGFR1068 antibody combination could selectively detect phosphorylated EGFR.
To assess the activation status of the mutant EGFRs, cells coexpressing various combinations of EGFRwt, EGFRvIII, and EGFRc958 were analyzed by in situ pEGFR PLA. Preformed EGFRwt homodimers were not active to a large extent, with full activation of receptors dependent on EGF ligand binding (Fig. 3A, bottom left,  and B) . In contrast, constitutively formed EGFRvIII homodimers may have functional importance, as reduced but persistent phosphorylated EGFRvIII dimers were detected (Fig. 3B) . The EGFRwt-EGFRvIII heterodimers also show constitutive phosphorylation, with a statistically significant further activation upon stimulation ( Fig. 3B ; P ¼ 0.0154). The mutant EGFRvIII-EGFRc958 heterodimers were also associated with low-level but constant activation. Levels of mutant dimerization and activation fell below levels for EGF-stimulated EGFRwt. This is consistent with a report showing that threshold levels of EGFRvIII and activation may be important for oncogenic signaling and defective downregulation (14) . Overall, these data show mutant EGFR dimerization complexes with quantitatively altered phosphoactivation profiles and likely associated aberrant downstream tumor-promoting signaling.
Aberrant dimerization and phosphorylation are independent of receptor expression levels
Receptor overexpression has been suggested to cause receptor clustering and spontaneous receptor activation (23) . Because our aforementioned observations of EGFR dimerization and activation were acquired from cell lines overexpressing EGFRs (i.e., >10 5 receptors per cell), we sought to discern whether receptor overexpression was responsible for spurious formation of (i) ligand-independent wild-type homodimers and (ii) aberrant mutant homo-and heterodimer complexes. To investigate the effects of surface EGFR expression levels on dimerization and activation, an inducible expression system was generated whereby the EGFR epitope-tag construct cytomegalovirus (CMV) promoter was replaced with a doxycycline-responsive TRE promoter. Previous reports suggest that less than 10 4 EGFRs per cell are critical for preventing overexpression artifacts and furthermore is a physiologically relevant level of receptor (23, 24) . Accordingly, we cotransfected CHOK1 cells with various combinations of TRE-EGFR epitope-tagged constructs and determined that a doxycycline concentration of 0.1 mg/ mL was sufficient to reproducibly generate cells expressing about 10 4 EGFRs per cell ( Supplementary Fig. S2 ). Quantitative in situ PLA for EGFR dimerization and EGFR phosphoactivation was then conducted on the various receptor combinations under low-level expression conditions.
Receptor overexpression itself was not responsible for preformed wild-type homodimers, as similar levels ($25%) of preformed dimers were observed under lowlevel expression (Fig. 4A) . Furthermore, the reduced levels of cellular EGFR did not impair the ability of mutant EGFRs to form dimers. Indeed, persistent EGFRvIII homodimers, EGFRwt-EGFRvIII heterodimers, and mutant EGFRvIII-EGFRc958 heterodimers could all be observed at similar relative levels. Interestingly, the induction of ligand-dependent EGFRc958 homodimers was far more dramatic under low-level expression compared with overexpression. These data suggest that EGFR overexpression commonly observed in GBMs, and genomic amplification-mediated overexpression, is not strictly required for mutant dimer formation but that the receptors themselves have intrinsic properties that facilitate EGFR interactions.
In addition, and of potential clinical importance, in situ PLA activation analysis indicated that low EGFR expression levels do not impair mutant phosphoactivation. In fact, EGFRvIII homodimer and EGFRwt-EGFRvIII and mutant EGFRvIII-EGFRc958 activation have higher relative levels, compared with that observed under overexpression conditions (Fig. 4B ). These observations show that cellular levels of EGFRwt dimerization and phosphorylation vary proportionally with receptor expression level. However, EGFRvIII-EGFRvIII, EGFRwt-EGFRvIII, and EGFRvIII-EGFRc958 have absolute levels of activation that are maintained independent of the total cellular levels of receptor.
Therapeutic anti-EGFR monoclonals have differential effects on mutant EGFR dimers
In situ PLA dimerization inhibition studies were conducted to assess the ability of clinically approved and investigational antibody-based EGFR therapies to block receptor dimerization. While several EGFR therapeutics exist for blocking ligand binding and subsequent dimerization, previous studies have focused on monitoring receptor activation as a measure of therapeutic efficacy (25, 26) . A better measure of efficacy would be to directly examine the dimerization event that these antibodies were designed to impair. Treatment doses for cetuximab, panitumumab, and matuzumab were established by treating EGFRwt-expressing cells with various concentrations of inhibitor and conducting immunoblot analysis for pEGFR levels. As expected, all therapeutics effectively blocked ligand-induced activation (Fig. 5A) . In situ pEGFR PLA analysis served as an alternative methodology for measuring EGFR mAb inhibition.
In situ pEGFR PLA analysis of EGFRwt-expressing cells treated with 10 mg/mL of mAbs, concurred with the immunoblot analysis, with a reduction in PLA signal observed (Fig. 5B) . Quantitative analysis confirmed the ability of the EGFR mAbs to block ligand-induced activation of EGFRs (Fig. 5C) . Furthermore, in situ PLA dimerization analysis showed that cetuximab, panitumumab, and matuzumab were able to achieve this effect by actually blocking ligand-induced homodimerization of the receptor (Fig. 5D) . Moreover, matuzumab showed significantly superior ability to impair EGFR phosphorylation than cetuximab (P ¼ 0.0009) and panitumumab (P ¼ 0.0052). This was likely due to enhanced inhibition of homodimerization compared with cetuximab (P ¼ 0.0040) and panitumumab (P ¼ 0.0081) as shown in Fig. 5D . These analyses highlight the potential use of in situ PLA for identifying and quantitatively evaluating anti-dimerization agents.
All antibody-based EGFR therapeutics to date have established their clinical dose based on their ability to block EGFRwt activity. It remains to be seen what efficacy these "EGFRwt-effective" doses will have on mutant EGFRs commonly expressed in GBMs, such as EGFRvIII and EGFRc958. To address this issue, we conducted in situ PLA dimerization and activation analysis on cells expressing various mutants that had been treated with EGFRwt-inhibiting doses of anti-EGFR mAbs cetuximab, panitumumab, and matuzumab. Interestingly, we observed that matuzumab had the greatest ability to significantly block EGFRvIII-EGFRvIII homodimer formation (Fig. 6A, black columns) . This finding implies that the established steric hindrance effects of matuzumab (27) are critical toward interfering with EGFRvIII interaction. In contrast, the indirect blockage of ligand binding by cetuximab and panitumumab is not important to a receptor which is unable to bind ligand to begin with (28) . Of interest, this apparent reduction in EGFRvIII homodimer levels had no significant effect on EGFRvIII receptor phosphorylation status (Fig. 6A-gray columns) . In line with these resistance observations, complementary Western blot analysis of receptor phosphorylation and downstream signaling confirmed that EGFRvIII-EGFRvIII homodimer containing cells had no apparent alterations to pEGFR1068, pERK, or p27 following mAb treatment (Fig. 6C, lanes 6-8  compared with lane 5) . Only matuzumab had a hint of inhibiting pAKT in EGFRvIII-expressing cells. Likewise, matuzumab, cetuximab, and panitumumab were also observed to significantly impair EGFRwt-EGFRvIII preformed dimers and prevent further interaction from ligand stimulation (Fig. 6B, black columns) . However, no mAb showed an ability to fully ablate basal EGFRwt-EGFRvIII heterodimer phosphorylation regardless of their ability to impair heterodimer formation (Fig. 6B, gray columns) . Interestingly, the greater potency of matuzumab toward EGFRwtEGFRvIII heterodimers observed in PLA experiments was also detected in Western blot signaling analysis. The observed trend was that matuzumab had modestly enhanced inhibition of pEGFR1068 and pAKT, compared with panitumumab and cetuximab (Fig. 6C, lane 12) . The enhanced signaling inhibition by matuzumab may be a secondary effect of increased receptor downregulation as it tended to downregulate EGFRvIII and EGFRwt-EGFRvIII, better than either cetuximab or panitumumab (Fig. 6C, EGFR blot) . Intriguingly, this increased downregulation of EGFRwtEGFRvIII by matuzumab also resulted in a paradoxical decrease in p27 levels perhaps indicating a decreased need for cell-cycle blockage because of concomitant decrease in oncogenic receptors. The preferential effect of matuzumab on EGFRwt-EGFRvIII heterodimers may have functional implications as the proliferation of GBM cell line U87-wt/vIII was reduced when treated with matuzumab ( Supplementary Fig.  S5 ). In terms of EGFRvIII-EGFRc958 heterodimer formation, none of the therapeutics had a dramatic effect on basal heterodimer levels, but all 3 were observed to inhibit the ligand-induced dimer fraction. Importantly, no substantial effects were observed on EGFRvIII-EGFRc958 phosphorylation, regardless of the anti-EGFR mAb tested. Supplementary Table S1 summarizes the level of dimerization and phosphorylation inhibition observed for the mAbs tested among various homo-and heterodimer configurations. Furthermore, these results hint at a nonconventional mechanism of EGFRvIII homodimeric association, independent of the canonical domain II dimerization arm that is deleted in EGFRvIII. The extracellular deletion in EGFRvIII may result in a dramatic rearrangement of the remaining extracellular domains yielding a novel dimerization interface for EGFRvIII interactions. Conversely, mutant EGFRvIII may dimerize in a domain IV-dependent manner, similar to that of the extracellular-deleted v-ErbB (29) . Eventual crystal structures of EGFRvIII may shed light on these outstanding questions. These analyses suggest that mutant EGFR dimers can evade anti-EGFR therapy, yet also point to the opportunity to block mutant EGFR activity depending on the specific mAb used. A corollary of these observations is that EGFRwt-inhibitory doses may be insufficient to block mutant EGFR function and the effects of higher level dosing remains to be seen.
Mutant EGFRwt-EGFRvIII heterodimers are present in GBM operative specimens
All published studies to date have evaluated mutant EGFR dimerization using in vitro cell culture models and are thus of limited relevance (9, (12) (13) (14) (15) . To address the possibility of mutant EGFRwt-EGFRvIII heterodimerization in GBM specimens, we profiled the EGFR expression status of 47 frozen samples of GBM operative specimens. RT-PCR and agarose gel analysis revealed the coexpression of EGFRvIII (243-bp product) and EGFRwt (1,044-bp product) in 5 of the samples tested: GBM2186, 2548, 2318, 2275, and 2230 ( Supplementary Fig. S3 ). Using this subgroup of EGFRwt and EGFRvIII coexpressing samples, we conducted in situ PLA for EGFRwt-EGFRvIII heterodimer analysis using anti-EGFRwt and anti-EGFRvIII-specific antibodies (Supplementary Fig. S4 ). In total 4 of 5 samples tested showed in situ PLA signal for EGFRwt-EGFRvIII dimers (Fig. 7) . Overall, tumors which expressed only one partner of the heterodimer (i.e., EGFRwt þ /EGFRvIII À ) showed the technical specificity of detection in the GBM samples, as these GBMs failed to generate any PLA signal (Fig. 7, GBM2539) . Notably, intrasample heterogeneity was apparent as regional variability in EGFRwt-EGFRvIII dimer signal could be observed within the same sample (Fig. 7, bottom middle) . It would appear that regional EGFRvIII expression differences, as observed in other reports, are partly responsible for the presence of EGFRwt-EGFRvIII dimers in some areas and lack of heterodimer signal in other areas of the same tumor (30) (31) (32) . We would therefore expect that some cells in the tumor samples tested were simply not coexpressing both EGFRwt and EGFRvIII and these cells failed to show EGFRwt-EGFRvIII heterodimer signal. Moreover, intersample heterogeneity was evident as EGFRwt-EGFRvIII Figure 7 . Direct in situ PLA EGFRwt-EGFRvIII detection was conducted using anti-EGFRvIII and anti-EGFRwt antibodies on formalin-fixed, paraffin-embedded (FFPE) GBM samples. Note the absence of PLA signal on tissue sample GBM2539 lacking EGFRvIII expression but positive for EGFRwt expression. Note the clear presence of bright, peripheral EGFRwt-EGFRvIII heterodimer signal on several GBM specimens (red; arrows). Cells were counterstained with Hoechst33258 (blue) to visualize nuclei; scale bars, 10 mm. dimer signals were variable among specimens, even though they coexpressed the EGFRwt and EGFRvIII receptors (Fig. 7, bottom right) . These data using PLA suggest a stoichiometric ratio of receptor expression level that favors heterodimer formation, as hinted by the differential EGFRwt:EGFRvIII expression ratios observed in our RT-PCR analysis (Supplementary Fig. S3 ).
Conclusions
Overall, this study illustrates that EGFR mutants prevalent in malignant gliomas possess aberrant interaction and activation features, as well as varied susceptibilities to anti-EGFR mAb therapies. Of novel clinical pertinence, EGFRwt-EGFRvIII mutant heterodimers were directly detected in GBM specimens. Further studies may determine whether there is a biologic or clinical relevance in the quantitative level and regional variability of EGFRwtEGFRvIII dimers within patient samples. For example, cells and/or regions of cells where mutant heterodimers are observed may be associated with differential downstream signaling (i.e., pAKT, pERK, pSTAT3, pPLCg, etc.) compared with cells lacking this mutant heterodimer thereby creating microenvironments of signaling activity. Furthermore, because EGFR amplification or expression in GBMs have limited use as prognostic factors for response to anti-EGFR therapeutics, the current data suggest further investigation of EGFR mutant dimerization as a potential parameter for predicting anti-EGFR therapy response.
